-
公开(公告)号：US20060263421A1
公开(公告)日：2006-11-23
申请号：US11380268
申请日：2006-04-26
申请人： Kalpana Patel , Suresh Borsadia
发明人： Kalpana Patel , Suresh Borsadia
IPC分类号： A61K31/573 , A61K31/41 , A61L15/16 , A61F13/02
CPC分类号： A61K9/7053 , A61K9/7061
摘要： Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive, wherein a plasma concentration of the 5-HT3 receptor antagonist in a therapeutically effective range is provided for period of time from an onset time to 12 hours or more after the composition is removed.
摘要翻译： 除了别的以外，还提供了一种治疗个体持续时间的急性，延迟或预期的呕吐的方法，其涉及对个体的完整皮肤的一部分施用i。 一种抗有效量的5-HT 3受体拮抗剂; ii。 渗透促进剂的渗透促进剂，其包含0.5〜15重量％的皮肤接触层; 和iii。 提供治疗有效范围的5-HT 3受体拮抗剂的血药浓度的粘合剂，其在除去组合物后从起始时间至12小时或更长时间。
-
公开(公告)号：US11707439B2
公开(公告)日：2023-07-25
申请号：US16840561
申请日：2020-04-06
CPC分类号： A61K31/13 , A61K9/0019 , A61K45/06
摘要： A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.
-
公开(公告)号：US20230082617A1
公开(公告)日：2023-03-16
申请号：US18049892
申请日：2022-10-26
申请人： Krunal Raval , Suresh Borsadia , Kalpana Patel
发明人： Krunal Raval , Suresh Borsadia , Kalpana Patel
摘要： The invention relates to a dosing regimen for administering a liquid pharmaceutical composition of amantadine hydrochloride to a patient having a traumatic brain injury. The dosing regimen includes administering a first dose and administering a second dose of amantadine hydrochloride. The step of administering a first dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The step of administering a second dose is by an intravenous route and the first dose comprises between 100 mg and 200 mg of amantadine hydrochloride in an aqueous solution of about 200 ml to about 300 ml over a period of about two to about four hours. The second dose is administered after at least about four to at least about six hours after the completion of administration of the first dose.
-
公开(公告)号：US20200315991A1
公开(公告)日：2020-10-08
申请号：US16840561
申请日：2020-04-06
摘要： A method and composition is described for treating impaired neurological function, CNS disease or condition, including altered state of consciousness disorders in a human subject, comprising parenterally administering a composition comprising aminoadamantane derivatives or salts thereof, alone or in combination with other neuroprotective and/or anti-inflammatory compounds, in a pharmacologically effective amount. In some embodiments, a method for treating traumatic brain injury caused by a stroke or an accident in a human subject is provided comprising intravenously administering a composition comprising amantadine hydrochloride in a pharmacologically effective amount to the subject in need thereof.
-
公开(公告)号：US20100158990A1
公开(公告)日：2010-06-24
申请号：US12521064
申请日：2007-12-26
申请人： Suresh Borsadia , Kalpana Patel
发明人： Suresh Borsadia , Kalpana Patel
IPC分类号： A61K9/70 , A61K31/573 , A61P29/00 , A61P9/10 , A61P1/08 , A61P35/00 , A61P7/10 , A61P31/00 , A61P11/06
CPC分类号： A61K9/7061
摘要： A method of treating an individual having a disease or for diagnostic purposes requiring administration of a corticosteroid, which involves applying to a portion of intact derma on the individual a transdermal patch having a backing layer and a matrix adhesive layer. The matrix adhesive layer includes a skin-compatible pressure-sensitive adhesive, a corticosteroid, and at least one permeation enhancer. The matrix adhesive layer, when applied to the skin of the individual, transdermally and continuously delivers the corticosteroid to the mammal for systemic treatment of the disease or for the diagnostic purpose.
摘要翻译： 治疗患有疾病或用于需要施用皮质类固醇的诊断目的的个体的方法，其涉及对个体的完整皮肤的一部分施用具有背衬层和基质粘合剂层的透皮贴剂。 基质粘合剂层包括皮肤相容的压敏粘合剂，皮质类固醇和至少一种渗透促进剂。 当将基质粘合剂层应用于个体的皮肤时，经皮和连续地将皮质类固醇递送至哺乳动物以全身治疗疾病或用于诊断目的。
-
公开(公告)号：US20070087044A1
公开(公告)日：2007-04-19
申请号：US11558663
申请日：2006-11-10
申请人： Kalpana Patel , Suresh Borsadia
发明人： Kalpana Patel , Suresh Borsadia
IPC分类号： A61K9/70
CPC分类号： A61K9/7053 , A61K9/7061
摘要： Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive.
摘要翻译： 除了别的以外，还提供了一种治疗个体持续时间的急性，延迟或预期的呕吐的方法，其涉及对个体的完整皮肤的一部分施用i。 一种抗有效量的5-HT 3受体拮抗剂; ii。 渗透促进剂的渗透促进剂，其包含0.5〜15重量％的皮肤接触层; 和iii。 粘合剂。
-
公开(公告)号：US20070098778A1
公开(公告)日：2007-05-03
申请号：US10595884
申请日：2005-02-28
申请人： Suresh Borsadia
发明人： Suresh Borsadia
IPC分类号： A61K31/426 , A61K31/401 , A61K31/366 , A61K31/22 , A61K31/155 , A61K9/48
CPC分类号： A61K9/209 , A61K9/1635 , A61K9/1652 , A61K9/5047 , A61K9/5084 , A61K31/155 , A61K31/22 , A61K31/366 , A61K31/401 , A61K31/41 , A61K31/426 , A61K45/06 , A61K2300/00
摘要： Provided, among other things, is a formulation or kit comprising: (a) a pharmaceutically effective dosage of one or more a glucose-level-controlling bioactive agents selected from an α-glucodase inhibitor, sulfonylurea, meglitinide, thiazolidinediones, biguanide, insulin, dual PPARα/γ agonist, PPARγ agonist or insulin secretagogue; and (b) a pharmaceutically effective dosage of (i) one or more of an antihypertensive bioactive agent selected from an ACE inhibitor, calcium channel blocker, beta blocker, angiotension II receptor antagonist or diuretic, or (ii) one or more of an anti-dyslipidemia bioactive agent selected from a HMG-CoA reductase inhibitor, bile acid sequestrant, fibric acid derivative, sterol, cholesterol absorption inhibitor, MTP inhibitor or nicotinic acid derivative; wherein: in the case of (i) a combination of a first bioactive agent of group (a) that is metformin with a second bioactive agent of group (b), or (ii) a combination of a first bioactive agent of group (a) that is a thiazolidinedione or dual PPARα/γ agonist with an angiotension II receptor antagonist, one or more of the following applies: (I) one of the first bioactive agent or the second bioactive agent is formulated for sustained release, and the other is formulated for immediate release, each formulated for once-a-day dosing; or (II) the co-formulation or kit comprises (A) a biguanide and a thiazolidinedione and (B) one or more group (b) bioactive agents.
摘要翻译： 本发明提供了一种制剂或试剂盒，其包含：（a）一种或多种一种或多种选自α-葡萄糖苷酶抑制剂，磺酰脲类，氯噻嗪类，噻唑烷二酮类，双胍类，胰岛素等的葡萄糖水平控制生物活性剂的药学有效剂量， 双重PPARα/γ激动剂，PPARγ激动剂或胰岛素促分泌素; 和（b）药学有效剂量的（i）一种或多种选自ACE抑制剂，钙通道阻滞剂，β阻滞剂，血管紧张素II受体拮抗剂或利尿剂的抗高血压生物活性剂，或（ii）一种或多种抗 选自HMG-CoA还原酶抑制剂，胆汁酸螯合剂，纤维酸衍生物，甾醇，胆固醇吸收抑制剂，MTP抑制剂或烟酸衍生物的 - 脂质血症生物活性剂; 其中：（i）组合式（a）的第二生物活性剂（其为二甲双胍）与组（b）的第二生物活性剂的组合，或（ii）组合的第一生物活性剂 ），其是具有血管紧张素II受体拮抗剂的噻唑烷二酮或双重PPARα/γ激动剂，其中一个或多个适用：（I）第一生物活性剂或第二生物活性剂之一被配制用于持续释放，另一种是 制备立即释放，每次配制一次一次给药; 或（II）共同制剂或试剂盒包含（A）双胍和噻唑烷二酮和（B）一种或多种组（b）生物活性剂。
-
公开(公告)号：US08246981B2
公开(公告)日：2012-08-21
申请号：US11558663
申请日：2006-11-10
申请人： Kalpana J Patel , Suresh Borsadia
发明人： Kalpana J Patel , Suresh Borsadia
IPC分类号： A61K9/70
CPC分类号： A61K9/7053 , A61K9/7061
摘要： Provided, among other things, is a method of treating acute, delayed or anticipatory emesis for a sustained period in an individual, which involves applying to a portion of intact skin on the individual a composition of i. an antiemetically effective amount of a 5-HT3 receptor antagonist; ii. a permeation enhancing amount of permeation enhancer comprising 0.5% to 15% by weight of the skin-contacting layer; and iii. an adhesive.
摘要翻译： 除了别的以外，还提供了一种治疗个体持续时间的急性，延迟或预期的呕吐的方法，其涉及对个体的完整皮肤的一部分施用i。 抗有效量的5-HT 3受体拮抗剂; ii。 渗透促进剂的渗透促进剂，其包含0.5〜15重量％的皮肤接触层; 和iii。 粘合剂。
-
公开(公告)号：US5774446A
公开(公告)日：1998-06-30
申请号：US580454
申请日：1995-12-27
申请人： Suresh Borsadia
发明人： Suresh Borsadia
CPC分类号： G11B7/0037 , G11B23/0014 , G11B25/02 , G11B27/002 , G11B27/102 , G11B2220/2545
摘要： The present invention relates to a segmented cylindrical audio-visual device (10) having interlocking disks (12) a first disk (12A) has a first disk bottom side (12AB) with a first disk bottom side female connector (12ABB) centrally positioned thereon. The adjacent second disk (12B) has a second disk top side (12BA) with a second disk top side male connector (12BAB) centrally positioned thereon. The second disk top side male connector (12BAB) is complimentary to and inserts into the first disk bottom side female connector (12ABB) thereby interlocking the first disk (12A) to the adjacent second disk (12B). Each interlocked disk (12) has a disk side (12AC . . . 12JC) having a respective disk side audio-visual track (12ACA . . . 12JCA) thereon. The respective disk side audio-visual tracks (12ACA . . . 12JCA) each represent a separate audio and/or visual track analogous to a song and a music video, respectively. By a user interlocking different disks (12) together a customized audio and visual ensemble is formulated.
摘要翻译： 本发明涉及具有互锁盘（12）的分段圆柱形视听装置（10），第一盘（12A）具有第一盘底侧（12AB），第一盘底侧（12AB）和第一圆盘底侧阴连接器（12ABB），中心定位在其上 。 相邻的第二盘（12B）具有第二盘顶侧（12BA），第二盘顶侧阳连接器（12BAB）位于其上。 第二盘顶侧阳连接器（12BAB）互补并插入第一盘底侧阴连接器（12ABB），从而将第一盘（12A）与相邻的第二盘（12B）互锁。 每个互锁盘（12）具有在其上具有相应的盘侧视听轨（12ACA ... 12JCA）的盘侧（12AC ... 12JC）。 相应的磁盘侧视听轨道（12ACA ... 12JCA）分别代表与歌曲和音乐视频类似的单独的音频和/或视频轨道。 通过用户将不同的盘（12）互锁在一起，定制的音视频集合。
-
公开(公告)号：US5626866A
公开(公告)日：1997-05-06
申请号：US544110
申请日：1995-10-17
IPC分类号： A61K9/70 , A61K31/465 , A61F13/00 , A61F13/02
CPC分类号： A61K9/703 , A61K9/7061
摘要： A method for making a transdermal drug delivery device for heat sensitive and volatile drugs is disclosed. The device contains a drug-containing adhesive composite layer having an impermeable backing material laminated to the distal surface thereof and a proximal peelable impermeable backing material adapted for removal for administering a drug to the skin or mucosa laminated to the proximal surface thereof. The method comprising the steps of providing first and second adhesive laminates each comprising a drug permeable adhesive layer having laminated to one surface one of said backing materials and having the opposing surface exposed. The drug, in gelled form and optionally containing additives such as enhancers and preservatives, is extruded onto at least one exposed surface of the first or second adhesive laminate followed by laminating together the exposed surfaces of the first and second adhesive laminate such that the adhesive layers and gelled drug are combined to form the drug-containing adhesive composite layer having the distal and proximal surfaces covered by the respective backing materials. The adhesives used in making up the laminates may be the same or different provided the drug is compatible with the adhesive. The process is particularly adaptable to the formulation of nicotine-containing patches. Drug delivery devices made according to the disclosed method and a method of using these drug delivery devices are also described.
摘要翻译： 公开了制备用于热敏和挥发性药物的透皮药物递送装置的方法。 该装置含有含有药物的粘合剂复合层，其具有层压到其远端表面的不可渗透的背衬材料和适于去除的药物的近侧可剥离的不渗透背衬材料，以将药物施用于层压到其近侧表面的皮肤或粘膜。 该方法包括以下步骤：提供第一和第二粘合剂层压体，每个粘合层压板包括药物可渗透的粘合剂层，该粘合剂层层压到所述背衬材料的一个表面并且具有暴露的相对表面。 将胶体形式的药物和任选地含有添加剂如增强剂和防腐剂的药物挤压到第一或第二粘合层压体的至少一个暴露表面上，然后将第一和第二粘合层压体的暴露表面层压在一起，使得粘合剂层 并且凝胶化药物组合以形成具有由各个背衬材料覆盖的远侧和近侧表面的含药物的粘合剂复合材料层。 用于组合层压体的粘合剂可以相同或不同，只要药物与粘合剂相容即可。 该方法特别适用于含尼古丁的贴剂的制剂。 还描述了根据所公开的方法制备的药物递送装置和使用这些药物递送装置的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.02 秒)
